GlaxoSmithKline’s Stiefel Laboratories Pays Welichem Biotech Inc. $50 Million for Topical Agent for Psoriasis, Atopic Dermatitis

VANCOUVER, May 30, 2012 /CNW/ - Stiefel, a GSK company, and Welichem Biotech Inc., have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights…
Read the full story: BioSpace.com Featured News